Lehne's Pharmacology for Nursing Care 10th Edition TEST
BANK(Chapter 1-110).
Chapters23:s2Drugs2Regulation,s2Development,s2Names,s2ands2Informat
ions2Tests2Bank
MULTIPLEs2CHOICE
1. As2nurses2educators2iss2conductings2as2continuings2educations2classs2ons2pharmacology.s2Tos
2evaluates2thes2learnings2ofs2thes2nursess2ins2thes2class,s2thes2nurses2educators2asks,s2―Whi
chs2drugs2names2iss2as2generics2drugs2name?‖s2Whichs2iss2thes2corrects2response?s2a.s2Acet
aminophen
b. Tylenol
c. Cipro
d. Motrin
ANS:s2A
Acetaminophens2iss2thes2generics2name.s2Tylenol,s2Cipro,s2ands2Motrins2ares2alls2trades2names.
DIF:s2Cognitives2Level:s2Comprehension REF:s2Tables23-
3:s2Thes2Threes2Typess2ofs2Drugs2Namess2TOP:s2Nursings2Process:s2Diagnosis
MSC:s2NCLEXs2Clients2Needss2Category:s2Physiologics2Integrity:s2Pharmacologics2ands2Parenterals2Therap
ies
2. Thes2FDAs2Amendmentss2Acts2(FDAAA)s2wass2passeds2ins22007s2tos2addresss2whichs2as
pects2ofs2drs2ugs2safety?
a. Allowings2pharmaceuticals2companiess2tos2identifys2
off-
s2labels2usess2ofs2medicationss2approveds2fors2others
2uses
b. Evaluatings2drugs2safetys2informations2thats2emergess2afters2as2drugs2hass2beens2appr
oveds2ands2iss2ins2use
c. Expeditings2thes2approvals2processs2ofs2thes2U.S.s2Foods2ands2Drugs2Administrations2
(FDA)s2ss2os2thats2neededs2drugss2cans2gets2tos2markets2mores2quickly
d. Requirings2manufacturerss 2 tos2 notifys2patientss 2 befores2 removings2 as2 drugs2 froms 2 thes 2 mark
et
ANS:s2 B
Thes2FDAAAs2wass2passeds2tos2enables2thes2Foods 2 ands 2 Drugs2Administrations2tos2continues2
oversights 2 ofs2as2drugs2afters2grantings2its2approvals2sos2thats2changess2ins2labelings2coulds2be
s 2 mades2ass2necessarys 2 ands2postmarketings2riskss2coulds2bes2trackeds2ands2identified.s2As2pr
ovisions2ofs2thes2FDAs2Modernizas2tions2 Acts2(FDAMA),s2passeds2ins 2 1997,s2allowss2drugs2c
ompaniess2tos2promotes2theirs2productss2fors2ofs 2 f-
labels2usess2ass2longs2ass2theys2promises2tos2conducts2studiess2tos2supports2theirs2claims.s2Regu
lationss2tos 2 permits2accelerateds2approvals2ofs2drugss2fors2life-
,Tests2Banks2Lehne'ss2Pharmacologys2fors2Nursings2Care,s211ths2E
dis2tions2bys2Jacquelines2Burchum,s2Lauras2Rosenthals2Chapters2
threatenings2diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2Thes2requirements2thats2drugs
1-s2112|Completes2Guides2A+
2companis 2 ess2notifys2patientss26s2monthss2befores2removings2as2drugs2froms2thes2markets2iss2
as2provisions2ofs2thes2Fs2DAMA.
DIF:s 2 Cognitives 2 Level:s 2 Comprehens
ion REF:s2Landmarks2Drugs2Legislation
TOP:s 2 Nursings2 Process:s 2 Evaluation
MSC:s2NCLEXs2Clients2Needss2Category:s2 Physiologics2 Integrity:s2 Pharmacologics2 ands2Parenterals2Th
erapies
,3. As2nursings2students2askss2as2nurses2abouts2pharmaceuticals2researchs2ands2wantss2tos2knows2
thes2purpos2ses2ofs 2 randomizations2ins 2 drugs 2 trials.s 2 Thes 2 nurses 2 explainss2thats 2 randomi
zations 2 iss2useds 2 to:
a. ensures2thats2differencess2ins2outcomess2ares2thes2results2ofs2treatments2ands2nots2di
fferencess2ins2subjects.
b. compares2 thes 2 outcomes 2 causeds 2 bys2thes 2 treatments 2 tos 2 thes2 outcomes2 causeds 2 bys2nos 2 treat
ment.
, Tests2Banks2Lehne'ss2Pharmacologys2fors2Nursings2Care,s211ths2E
dis2tions2bys2Jacquelines2Burchum,s2Lauras2Rosenthals2Chapters2
1-s2112|Completes2Guides2A+
c. makes2 sures2 thats 2 researcherss 2 ares2 unawares2 ofs 2 whichs 2 subjectss 2 ares2 ins 2 whichs 2 group.
d. prevents2subjectss2froms2knowings2whichs2groups2theys2ares2ins2ands2prevents2prec
onceptios2ns2bias.
ANS:s2 A
Randomizations2helpss2prevents2allocations2bias,s2whichs2cans2occurs2whens2researcherss2place
s2subjecs2tss2withs2desireds2characteristicss2ins2thes2studys2groups2ands2others2subjectss2ins2thes2
controls2groups2sos2ts2hats 2 differencess 2 ins2 outcomes2 ares2 actuallys2thes 2 results2 ofs2 difference
ss 2 ins 2 subjectss 2 ands2 nots 2 treatmens2t.
Comparings2treatments2 outcomes2 tos2 nos2 treatments2 outcomes2 iss2 thes2 definitions2 ofs2 as2 controll
eds2 stud
y.s2Thes2lasts2twos2optionss2describes2thes2uses2ofs2blindings2ins2studies;s2blindings2ensuress2th
ats2researcs2herss2ors2subjectss2(ors2both)s2ares2unawares2ofs2whichs2subjectss2ares2ins2whichs2g
roups2sos2thats2preconcs2eptionss2abouts2benefitss2ands2riskss2cannots2biass2thes2results.
DIF:s 2 Cognitives 2 Level:s 2 Comprehensi
on REF:s2Thes2Randomizeds2Drugs2Tria
ls 2 TOP:s 2 Nursings 2 Process:s 2 Implement
ation
MSC:s2NCLEXs2Clients2Needss2Category:s2 Physiologics2 Integrity:s2 Pharmacologics2 ands2Parenterals2Th
erapies
4. Someones2askss2 as2nurses2 abouts2as2news2drugs2thats2iss2 ins2preclinicals2 testings2ands 2 wantss
2tos2knows2 whs 2 ys2its 2 cannots 2 bes 2 useds 2 tos 2 treats 2 as 2 friend‘ss 2 illness.s 2 Whichs 2 stateme
nts 2 bys 2 thes 2 nurses 2 iss 2 correct?
a. ―As2 drugs2 ats2 thiss2 stages2 ofs2 developments 2 cans 2 bes2 useds2 onlys2ins 2 patientss2 withs2 seriou
ss2 disease.‖
b. ―Ats2thiss2stages2ofs2drugs2development,s2thes2safetys2ands2usefulnesss2ofs2thes2m
edications2iss2unknown.‖
c. ―Clinicals2 trialss2 musts2 bes2 completeds 2 tos2 makes2 sures 2 thes 2 drugs2 iss2 safes2 tos2 uses2 ins 2 hu
mans.‖
d. ―Untils2 postmarketings2 surveillances 2 datas 2 ares2 available,s2 thes2 drugs2 cannots 2 bes2 used.‖
ANS:s2 B
Preclinicals2testings2musts2bes2completeds2befores2drugss2cans2bes2testeds2ins2humans.s2Ins2th
iss2stage,s2drugss 2 ares 2 evaluateds 2 fors2 toxicities,s2 pharmacokinetics 2 properties,s 2 ands 2 pote
ntiallys2 usefuls 2 effect
s.s2Somes2drugss2cans2bes2useds2ins2patientss2befores2completions2ofs2Phases2IIIs2studies,s2but
s2thiss2iss2afs 2 ters2preclinicals2testings2iss2complete.s2Clinicals2trialss2proceeds2ins2stages,s2an
ds2eachs2stages2hass2guids2eliness2definings2hows2as2news2drugs2mays2bes2useds2ands2whichs2
patientss2mays2receives2it.s2Postmarks2etings2surveillances2takess2places2afters2as2drugs2iss2ins
2generals2use.
DIF:s2 Cognitives2 Level:s2 Comprehension
REF:s2Landmarks2Drugs2Legislations2|s2Stagess2ofs2Drugs2Developm
ents2Ts2OP:s2Nursings2Process:s2Implementation
MSC:s2NCLEXs2 Clients2 Needss2 Category:s2 Physiologics2 Integrity:s2 Reductions2 ofs2 Risks2 Potential
BANK(Chapter 1-110).
Chapters23:s2Drugs2Regulation,s2Development,s2Names,s2ands2Informat
ions2Tests2Bank
MULTIPLEs2CHOICE
1. As2nurses2educators2iss2conductings2as2continuings2educations2classs2ons2pharmacology.s2Tos
2evaluates2thes2learnings2ofs2thes2nursess2ins2thes2class,s2thes2nurses2educators2asks,s2―Whi
chs2drugs2names2iss2as2generics2drugs2name?‖s2Whichs2iss2thes2corrects2response?s2a.s2Acet
aminophen
b. Tylenol
c. Cipro
d. Motrin
ANS:s2A
Acetaminophens2iss2thes2generics2name.s2Tylenol,s2Cipro,s2ands2Motrins2ares2alls2trades2names.
DIF:s2Cognitives2Level:s2Comprehension REF:s2Tables23-
3:s2Thes2Threes2Typess2ofs2Drugs2Namess2TOP:s2Nursings2Process:s2Diagnosis
MSC:s2NCLEXs2Clients2Needss2Category:s2Physiologics2Integrity:s2Pharmacologics2ands2Parenterals2Therap
ies
2. Thes2FDAs2Amendmentss2Acts2(FDAAA)s2wass2passeds2ins22007s2tos2addresss2whichs2as
pects2ofs2drs2ugs2safety?
a. Allowings2pharmaceuticals2companiess2tos2identifys2
off-
s2labels2usess2ofs2medicationss2approveds2fors2others
2uses
b. Evaluatings2drugs2safetys2informations2thats2emergess2afters2as2drugs2hass2beens2appr
oveds2ands2iss2ins2use
c. Expeditings2thes2approvals2processs2ofs2thes2U.S.s2Foods2ands2Drugs2Administrations2
(FDA)s2ss2os2thats2neededs2drugss2cans2gets2tos2markets2mores2quickly
d. Requirings2manufacturerss 2 tos2 notifys2patientss 2 befores2 removings2 as2 drugs2 froms 2 thes 2 mark
et
ANS:s2 B
Thes2FDAAAs2wass2passeds2tos2enables2thes2Foods 2 ands 2 Drugs2Administrations2tos2continues2
oversights 2 ofs2as2drugs2afters2grantings2its2approvals2sos2thats2changess2ins2labelings2coulds2be
s 2 mades2ass2necessarys 2 ands2postmarketings2riskss2coulds2bes2trackeds2ands2identified.s2As2pr
ovisions2ofs2thes2FDAs2Modernizas2tions2 Acts2(FDAMA),s2passeds2ins 2 1997,s2allowss2drugs2c
ompaniess2tos2promotes2theirs2productss2fors2ofs 2 f-
labels2usess2ass2longs2ass2theys2promises2tos2conducts2studiess2tos2supports2theirs2claims.s2Regu
lationss2tos 2 permits2accelerateds2approvals2ofs2drugss2fors2life-
,Tests2Banks2Lehne'ss2Pharmacologys2fors2Nursings2Care,s211ths2E
dis2tions2bys2Jacquelines2Burchum,s2Lauras2Rosenthals2Chapters2
threatenings2diseasess2weres2adopteds2ins21992s2bys2thes2FDA.s2Thes2requirements2thats2drugs
1-s2112|Completes2Guides2A+
2companis 2 ess2notifys2patientss26s2monthss2befores2removings2as2drugs2froms2thes2markets2iss2
as2provisions2ofs2thes2Fs2DAMA.
DIF:s 2 Cognitives 2 Level:s 2 Comprehens
ion REF:s2Landmarks2Drugs2Legislation
TOP:s 2 Nursings2 Process:s 2 Evaluation
MSC:s2NCLEXs2Clients2Needss2Category:s2 Physiologics2 Integrity:s2 Pharmacologics2 ands2Parenterals2Th
erapies
,3. As2nursings2students2askss2as2nurses2abouts2pharmaceuticals2researchs2ands2wantss2tos2knows2
thes2purpos2ses2ofs 2 randomizations2ins 2 drugs 2 trials.s 2 Thes 2 nurses 2 explainss2thats 2 randomi
zations 2 iss2useds 2 to:
a. ensures2thats2differencess2ins2outcomess2ares2thes2results2ofs2treatments2ands2nots2di
fferencess2ins2subjects.
b. compares2 thes 2 outcomes 2 causeds 2 bys2thes 2 treatments 2 tos 2 thes2 outcomes2 causeds 2 bys2nos 2 treat
ment.
, Tests2Banks2Lehne'ss2Pharmacologys2fors2Nursings2Care,s211ths2E
dis2tions2bys2Jacquelines2Burchum,s2Lauras2Rosenthals2Chapters2
1-s2112|Completes2Guides2A+
c. makes2 sures2 thats 2 researcherss 2 ares2 unawares2 ofs 2 whichs 2 subjectss 2 ares2 ins 2 whichs 2 group.
d. prevents2subjectss2froms2knowings2whichs2groups2theys2ares2ins2ands2prevents2prec
onceptios2ns2bias.
ANS:s2 A
Randomizations2helpss2prevents2allocations2bias,s2whichs2cans2occurs2whens2researcherss2place
s2subjecs2tss2withs2desireds2characteristicss2ins2thes2studys2groups2ands2others2subjectss2ins2thes2
controls2groups2sos2ts2hats 2 differencess 2 ins2 outcomes2 ares2 actuallys2thes 2 results2 ofs2 difference
ss 2 ins 2 subjectss 2 ands2 nots 2 treatmens2t.
Comparings2treatments2 outcomes2 tos2 nos2 treatments2 outcomes2 iss2 thes2 definitions2 ofs2 as2 controll
eds2 stud
y.s2Thes2lasts2twos2optionss2describes2thes2uses2ofs2blindings2ins2studies;s2blindings2ensuress2th
ats2researcs2herss2ors2subjectss2(ors2both)s2ares2unawares2ofs2whichs2subjectss2ares2ins2whichs2g
roups2sos2thats2preconcs2eptionss2abouts2benefitss2ands2riskss2cannots2biass2thes2results.
DIF:s 2 Cognitives 2 Level:s 2 Comprehensi
on REF:s2Thes2Randomizeds2Drugs2Tria
ls 2 TOP:s 2 Nursings 2 Process:s 2 Implement
ation
MSC:s2NCLEXs2Clients2Needss2Category:s2 Physiologics2 Integrity:s2 Pharmacologics2 ands2Parenterals2Th
erapies
4. Someones2askss2 as2nurses2 abouts2as2news2drugs2thats2iss2 ins2preclinicals2 testings2ands 2 wantss
2tos2knows2 whs 2 ys2its 2 cannots 2 bes 2 useds 2 tos 2 treats 2 as 2 friend‘ss 2 illness.s 2 Whichs 2 stateme
nts 2 bys 2 thes 2 nurses 2 iss 2 correct?
a. ―As2 drugs2 ats2 thiss2 stages2 ofs2 developments 2 cans 2 bes2 useds2 onlys2ins 2 patientss2 withs2 seriou
ss2 disease.‖
b. ―Ats2thiss2stages2ofs2drugs2development,s2thes2safetys2ands2usefulnesss2ofs2thes2m
edications2iss2unknown.‖
c. ―Clinicals2 trialss2 musts2 bes2 completeds 2 tos2 makes2 sures 2 thes 2 drugs2 iss2 safes2 tos2 uses2 ins 2 hu
mans.‖
d. ―Untils2 postmarketings2 surveillances 2 datas 2 ares2 available,s2 thes2 drugs2 cannots 2 bes2 used.‖
ANS:s2 B
Preclinicals2testings2musts2bes2completeds2befores2drugss2cans2bes2testeds2ins2humans.s2Ins2th
iss2stage,s2drugss 2 ares 2 evaluateds 2 fors2 toxicities,s2 pharmacokinetics 2 properties,s 2 ands 2 pote
ntiallys2 usefuls 2 effect
s.s2Somes2drugss2cans2bes2useds2ins2patientss2befores2completions2ofs2Phases2IIIs2studies,s2but
s2thiss2iss2afs 2 ters2preclinicals2testings2iss2complete.s2Clinicals2trialss2proceeds2ins2stages,s2an
ds2eachs2stages2hass2guids2eliness2definings2hows2as2news2drugs2mays2bes2useds2ands2whichs2
patientss2mays2receives2it.s2Postmarks2etings2surveillances2takess2places2afters2as2drugs2iss2ins
2generals2use.
DIF:s2 Cognitives2 Level:s2 Comprehension
REF:s2Landmarks2Drugs2Legislations2|s2Stagess2ofs2Drugs2Developm
ents2Ts2OP:s2Nursings2Process:s2Implementation
MSC:s2NCLEXs2 Clients2 Needss2 Category:s2 Physiologics2 Integrity:s2 Reductions2 ofs2 Risks2 Potential
